• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Ophthonix picks Osbaldeston as chief executive officer


Ophthonix has named Stephen J. Osbaldeston as its chief executive officer.

Key Points

San Diego-Ophthonix has named Stephen J. Osbaldeston as its chief executive officer (CEO), succeeding Andreas Dreher, PhD, who had been chairman of the board and CEO.

Dr. Dreher will retain his position as chairman of the board and take on the role of chief technology officer, where he will oversee research and development and engineering.

Osbaldeston has more than 20 years of experience in the eye-care field, including positions with CIBA Vision, where he was president, global specialty lens and lens care. He also worked at Bausch & Lomb.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.